CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. COLLABORATION AND EXCLUSIVE...Collaboration and Exclusive License Agreement • June 23rd, 2014 • Ambrx Inc • Pharmaceutical preparations • New York
Contract Type FiledJune 23rd, 2014 Company Industry JurisdictionTHIS COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (ADC) (the “Agreement”) is made and entered into effective as of May 2, 2013 (the “Effective Date”) by and between AMBRX, INC., a Delaware corporation having its principal place of business at 10975 North Torrey Pines Road, La Jolla, CA 92037 (“Ambrx”) and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”). Ambrx and BMS are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. COLLABORATION AND EXCLUSIVE...Collaboration and Exclusive License Agreement • May 2nd, 2014 • Ambrx Inc • Pharmaceutical preparations • New York
Contract Type FiledMay 2nd, 2014 Company Industry JurisdictionTHIS COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT (ADC) (the “Agreement”) is made and entered into effective as of May 2, 2013 (the “Effective Date”) by and between AMBRX, INC., a Delaware corporation having its principal place of business at 10975 North Torrey Pines Road, La Jolla, CA 92037 (“Ambrx”) and BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“BMS”). Ambrx and BMS are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.